LEADER 02115nam  2200505I  450 
001 9910713508703321
005 20200611093437.0
035   $a(CKB)5470000002502581
035   $a(OCoLC)1156966114
035   $a(EXLCZ)995470000002502581
100   $a20200605d2020      ua             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aDrug safety: COVID-19 complicates already challenged FDA foreign inspection program $etestimony before the Committee on Finance, U.S. Senate /$fstatement of Mary Denigan-Macauley
210  1$a[Washington, D.C.] :$cUnited States Government Accountability Office,$d2020.
215   $a1 online resource (26 pages) $ccolor illustrations, color maps
225 1 $aTestimony ;$vGAO-20-626-T
300   $a"For release on delivery, expected at 2:30 p.m. ET, Tuesday, June 2, 2020."
320   $aIncludes bibliographical references.
517   $aDrug safety
606   $aCOVID-19 (Disease)$xTreatment$zUnited States
606   $aDrugs$xInspection$zUnited States
606   $aDrugs$zUnited States$xSafety measures$xEvaluation
606   $aPharmaceutical industry$xQuality control$xEvaluation
606   $aDrugs$xSafety regulations$zUnited States$xEvaluation
606   $aDrug reimportation$zUnited States$xEvaluation
606   $aImports$zUnited States$xSafety measures$xEvaluation
615  0$aCOVID-19 (Disease)$xTreatment
615  0$aDrugs$xInspection
615  0$aDrugs$xSafety measures$xEvaluation.
615  0$aPharmaceutical industry$xQuality control$xEvaluation.
615  0$aDrugs$xSafety regulations$xEvaluation.
615  0$aDrug reimportation$xEvaluation.
615  0$aImports$xSafety measures$xEvaluation.
702   $aDenigan-Macauley$b Mary
712 02$aUnited States.$bCongress.$bSenate.$bCommittee on Finance,
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910713508703321
996   $aDrug safety: COVID-19 complicates already challenged FDA foreign inspection program$93445754
997   $aUNINA